Arphra/Issuer/VRTX

VRTX

Vertex Pharmaceuticals Incorporated

HealthcareBiotechnologyUSUSD

$438.40

+0.50%LiveJun 01, 2026

AI Brief

Market cap

$111.27B

52w range

362.50 – 507.92

P / E

—

EPS

—

Volume

1.11M

Revenue · FY

$12.07B

+9.57% YoY

Explain this page

Arphra AIPlain-English read on Vertex Pharmaceuticals Incorporated’s valuation

AI Issuer Brief

Arphra AI

Loading cached brief…

Insider · 30d

Bought

0 txns

Sold

$8.21M

10 txns

Net flow

−$8.21M

Full history →

Price

DB · prices_daily

1M 6M 1Y 5Y

Last

$425.84

Change

-4.40%

Period high

$499.17

Period low

$366.54

Period start

$445.432025-06-02

Through 2026-05-04

Peers

Price change · trailing returns

Live

1D	5D	1M	3M	6M	YTD	1Y	3Y	5Y	10Y	Max
-2.04%	-0.03%	+3.42%	-11.76%	+3.01%	-3.30%	-1.58%	+35.47%	+109.09%	+366.88%	+9642.22%

Aftermarket

Live

Jun 01, 11:47 PM

Last trade

$437.90

448 sh

Bid

$431.10

2 sh

Ask

$438.98

8 sh

Spread

$7.880

Sector & industry today

Live

Sectors

Technology
+0.67%
Basic Materials
+0.15%
Communication Services
+0.13%
Real Estate
-0.13%
Industrials
-0.48%
Energy
-0.58%
Healthcare
-0.65%
Financial Services
-0.80%
Consumer Defensive
-0.85%
Consumer Cyclical
-0.85%
Utilities
-1.15%

Top industries (issuer's industry highlighted)

Biotechnology
+3.22%
Computer Hardware
+8.35%
Software - Infrastructure
+7.61%
Coal
+5.76%
Consulting Services
+5.28%
Medical - Healthcare Information Services
+5.23%
Medical - Diagnostics & Research
+4.96%
REIT - Healthcare Facilities
-3.49%
Broadcasting
-3.48%
Software - Application
+3.44%
Advertising Agencies
+3.24%
Travel Services
+3.21%

Fair value

Football field →

Weighted blend

$2,167.98

+394.52% vs spot

Recommendation

Strong Buy

15 of 16 methods

Method spread

4bull11bear

±5% threshold

Analyst PT consensus: $552.27 (+25.97%)

Total assets

$26.14B

Total debt

$3.88B

Cash & equiv

$5.09B

Operating CF

$3.63B

Free cash flow

$3.19B

Buybacks

-$2.02B

Analyst view

DB · price_targets + analyst_grades

Consensus target

$552.27

+25.97% upside

Low

$437.00

Median

$558.00

High

$612.00

Recent actions

0 ↑0 ↓8 hold

Apr 01, 2026
Mar 01, 2026
Feb 01, 2026
Jan 01, 2026
Dec 01, 2025

News

DB · news_items

Recent quarters

All financials →

Period	Revenue	Net income	EPS
Q4 Dec 2025	$3.23B	$1.19B	$4.65
Q3 Sep 2025	$3.08B	$1.08B	$4.20
Q2 Jun 2025	$2.96B	$1.03B	$3.99
Q1 Mar 2025	$2.77B	$646.3M	$2.49
Q4 Dec 2024	$2.91B	$913M	$3.50
Q3 Sep 2024	$2.77B	$1.05B	$4.01

Recent insiders

All →

Insider	Action	Shares	Value	Date
Bhatia Sangeeta N. director	Sell	318	$134.75K	May 04, 2026
Liu Joy officer: EVP and Chief Legal Officer	Sell	1,104	$469.22K	May 01, 2026
Liu Joy officer: EVP and Chief Legal Officer	Sell	978	$439.29K	Apr 01, 2026
Bozic Carmen officer: EVP and CMO	Sell	2,329	$1.05M	Mar 27, 2026
Bozic Carmen officer: EVP and CMO	Sell	2,329	$1.12M	Mar 13, 2026
McKechnie Duncan officer: EVP, Chief Commercial Officer	Sell	2,633	$1.31M	Mar 11, 2026

Income statement · annual

Open Financials →

Period	Revenue	Op income	Net income	EPS	Net margin
FY 2025	$12.07B	$4.76B	$3.95B	$15.32	+32.74%
FY 2024	$11.02B	-$232.9M	-$535.6M	$-2.08	-4.86%
FY 2023	$9.87B	$3.83B	$3.62B	$13.89	+36.68%
FY 2022	$8.93B	$4.31B	$3.32B	$12.82	+37.20%
FY 2021	$7.57B	$2.78B	$2.34B	$9.01	+30.92%